Deallus white papers

The latest white papers from Deallus pharmaceutical and life science industry experts

China Pharma Market Access (CPMA)

2023-09-13T12:05:52+01:00News, White Paper|

Since the establishment of the China National Medical Insurance Bureau in 2018, the goal has been to strengthen public health and medical service levels, achieve maximum utilisation of the national medical insurance fund, and to enhance the strategic purchasing capability of medical insurance funds. Significant tools in achieving this are the National Reimbursement Drug List (NRDL) and drug Volume Based Procurement (VBP), which have opened a new chapter in China’s medical reform. Meanwhile, the new drug registration process is improved, simplified, and accelerated.

HIV/AIDS

2022-12-01T11:26:10+00:00News, White Paper|

Human immunodeficiency virus (HIV) is the virus that is responsible for Acquired Immune Deficiency Syndrome (AIDS). HIV continues to be a major global public health issue having claimed the lives of 36.3 million people so far, according to World Health Organization (WHO).

Deallus Workshops: providing competitive advantage through Competitive Simulation

2022-11-24T09:54:46+00:00White Paper|

Competitive Simulation, also known as Competitive Strategy or ‘Wargaming’ workshops, account for roughly 85% of the workshops that Deallus run. We have developed a detailed and comprehensive workshop playbook that ensures our teams are well-prepared and well-versed with a set of tools ready to run your sessions.

The future for telehealth and neuroscience in the US

2022-06-01T14:30:15+01:00White Paper, Thought Piece|

Catalyzed by Covid-19, the accelerated uptake of virtual services within neuroscience has set in motion a reimagining of future healthcare pathways. The new post-pandemic reality is a hybrid virtual/in-person approach for many neurological and psychiatric conditions - driving rapid regulatory change, reduced delivery costs, and improved patient access.

Go to Top